An open-label extension study of subcutaneous efgartigimod PH20 for treating chronic inflammatory demyelinating polyneuropathy (CIDP) showed durable functional improvements up to week 24 with no new safety signals. The study involved the FDA-approved coformulation of efgartigimod alfa and hyaluronidase-qvfc for CIDP treatment. Patients in the study demonstrated high adherence to the treatment, with participants who relapsed in the study showing clinical improvement with efgartigimod PH20. The drug works by lowering IgG levels without affecting production. The study reported no new safety concerns, with high tolerability, and the drug can be self-administered at home, providing a new treatment option for CIDP patients.
Source link
CIDP Benefits Persist in Efgartigimod Open-Label Extension
